



# BloodTrain Next Generation

Availability, Quality and Safety of Blood and Blood Products in Africa

## Context

The availability, safety and quality of blood and blood products is an essential component of any health care system. The WHO has therefore listed them as essential medicines. Blood products are life-saving for many patients, in particular for women with pregnancy-related complications, children suffering from severe anaemia and people with traffic injuries. However, in many African countries, blood and blood products of an acceptable quality are not available in sufficient quantity. To address this issue, it is imperative to strengthen regulatory mechanisms, including for the licensing and inspection of blood establishments, haemovigilance and the licensing of in vitro diagnostics for blood-borne pathogens. In the first phase, the project laid the foundations, introducing benchmarking systems, providing training and working on regulatory documents. BloodTrain Next Generation aims to further expand regulatory capacities in the partner countries. To ensure sustainable competence development, the project supports the formation of regional centres of regulatory excellence for blood regulation, where regulators from neighbouring countries will be trained. Working with organisations such as AUDA-NEPAD and AfsBT, the project holds workshops and supports the establishment of pan-African guidelines to enhance the harmonisation of regulatory frameworks for blood and blood products all over Africa.

## Objective

Strengthening the regulation of blood and blood products in Africa to increase their availability, quality and safety and to harmonise regulatory requirements at the continental level.

## Key facts

### Duration

1 January 2023 to 31 December 2025

### Budget


~ EUR 2.6 million

### Partner countries

Ghana, Nigeria, Tanzania, Zambia, Zimbabwe

### Region

Western, Eastern and Southern Africa



### Implemented by

Paul-Ehrlich-Institut (PEI)

### Commissioning party

German Federal Ministry of Health (BMG)

## Thematic focus

Strengthening of public health systems

Marketing authorisation and safety of medicinal products

## Activities



### TRAINING AND COMPETENCE DEVELOPMENT

Training the employees of national regulatory authorities and blood establishments to ensure blood safety in the blood sector and developing training capacities (train-the-trainer approach) on regulatory mechanisms



### CAPACITY DEVELOPMENT

Developing regulatory structures by evaluating the status of the regulatory system and providing technical support to further strengthen it, for example, by developing guidance documents in the partner countries



### NETWORKING AND COOPERATION

Mediating in the development of pan-African guidelines and conducting workshops with regional organisations to promote the harmonisation of regulatory requirements at the continental level

## In cooperation with

- Food and Drugs Authority (FDA), Ghana
- Tanzania Medicines and Medical Devices Authority (TMDA), Tanzania
- National Agency for Food and Drug Administration and Control (NAFDAC), Nigeria
- Medicines Control Authority of Zimbabwe (MCAZ), Zimbabwe
- Zambia Medicines Regulatory Authority (ZAMRA), Zambia
- African Union Development Agency, New Partnership for Africa's Development (AUDA-NEPAD), South Africa
- Africa Society for Blood Transfusion (AfSBT), South Africa

## Contact

Dr Jens Reinhardt

Paul-Ehrlich-Institut (PEI)

Paul-Ehrlich-Straße 51-59,  
63225 Langen, Germany

[bloodtrain@pei.de](mailto:bloodtrain@pei.de)

**GHPP, the Global Health Protection Programme** of the German Federal Ministry of Health, promotes networking, exchange and cooperation between specialized German and international public health actors. By reducing health risks and strengthening health systems at the national, regional and international level, in particular relating to pandemic and epidemic preparedness and response, the GHPP fosters public health protection – worldwide.

Paul-Ehrlich-Institut   
Federal Institute for Vaccines  
and Biomedicines

Supported by:



on the basis of a decision  
by the German Bundestag